Company Encyclopedia
View More
name
Regenxbio
RGNX.US
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease.
1.946 T
RGNX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking114/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-76.88%E
    • Profit Margin-110.29%E
    • Gross Margin-107.94%E
  • Growth ScoreB
    • Revenue YoY91.30%A
    • Net Profit YoY25.50%B
    • Total Assets YoY1.17%C
    • Net Assets YoY-46.44%E
  • Cash ScoreB
    • Cash Flow Margin-90.67%D
    • OCF YoY91.30%A
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreD
    • Gearing Ratio69.26%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Regenxbio files $300M mixed shelf offering

    Regenxbio (RGNX) has filed a shelf registration to offer up to $300M in securities, including common stock, preferred stock, debt securities, warrants, rights, or units, in various combinations and tranches.

    MSN·
    US
    RGNX
    +0.78%
    MSN·
    US
    RGNX
    +0.78%

    Regenxbio Files For Mixed Shelf Of Up To $300 Million - SEC Filing

    Nov 26 (Reuters) - Regenxbio Inc:* REGENXBIO INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    RGNX
    +0.78%
    Reuters·
    US
    RGNX
    +0.78%

    REGENXBIO (NASDAQ:RGNX) Trading Up 10.7% After Analyst Upgrade

    REGENXBIO's stock rose 10.7% after Wall Street Zen upgraded it from a sell to a hold rating. The stock traded at $13.54, with a significant decrease in trading volume. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $28.63. Insider trading and institutional investments were also noted, with significant holdings by JPMorgan Chase, Vanguard, and others. The company reported better-than-expected earnings, with a negative return on equity and net margin.

    Market Beat·
    US
    RGNX
    +0.78%
    Market Beat·
    US
    RGNX
    +0.78%

    Regenxbio Inc. to Join Piper Sandler Healthcare Conference

    Regenxbio Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat on December 2 at 8:30 a.m. ET in New York. A live webcast will be available on the company's website, with a replay accessible for 30 days. This information was originally published by Regenxbio Inc. via PR Newswire.

    Reuters·
    US
    RGNX
    +0.78%
    Reuters·
    US
    RGNX
    +0.78%

    REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital

    Chardan Capital reiterated a "buy" rating for REGENXBIO with a $52.00 price target, suggesting a 375.75% upside. Other analysts have mixed ratings, including "sell" and "hold." The stock opened at $10.93, with a market cap of $553.28 million. Insider activity includes CEO selling shares. Institutional investors hold 88.08% of the stock. REGENXBIO focuses on gene therapies using NAV Technology Platform.

    Market Beat·
    US
    RGNX
    +0.78%
    Market Beat·
    US
    RGNX
    +0.78%
    © 2025 Longbridge｜Disclaimer